Eligible AACR 2019 Annual Meeting Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 25 of 46
[18F]-alpha-V-beta-3 Integrin PET Imaging as a Biomarker of Clinical Angiogenesis
Pamela S. Cohen, M.D.
GE Healthcare, Princeton, NJ
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 11:00 AM-1:00 PM
Individualizing Cancer Therapies using PET Imaging
Richard L. Wahl, M.D.
Johns Hopkins University, Baltimore, MD
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 11:00 AM-1:00 PM
Application of Molecular Imaging in Cancer Drug Development and Clinical Trials
Brian D. Ross, Ph.D.
University of Michigan, Ann Arbor, MI
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 11:00 AM-1:00 PM
High Quality Copy Number and Genotype from FFPE Samples Using Molecular Inversion Probes (MIP)
Malek Faham, M.D., Ph.D.
Affymetrix, South San Francisco, CA
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 11:00 AM-1:00 PM
Mitochondrial Dysregulation and Molecular Diagnostics
Joseph A. Califano, M.D.
Johns Hopkins University School of Medicine, Baltimore, MD
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 11:00 AM-1:00 PM
Epigenetic Contributions to Human Malignancies
Christoph Plass, Ph.D.
Ohio State University, Columbus, OH
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 11:00 AM-1:00 PM
The Use of Biomarkers in Early Clinical Trials at the NCI
Joseph E. Tomaszewski, Ph.D.
National Cancer Institute, Bethesda, MD
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 2:00 PM-4:00 PM
Evaluating When a Diagnostic Test or Biomarker is Informative
Dr. Gregory Campbell
Center for Devices and Radiological Health, FDA, Rockville, MD
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 2:00 PM-4:00 PM
Translational Use of Imaging in Early Drug Development
Susan M. Galbraith, Ph.D.
Bristol-Myers Squibb Company, Princeton, NJ
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 2:00 PM-4:00 PM
Econogenomics 2007: When Does the Inclusion of Biomarkers in Oncology Drug Development Make Economic Sense?
Dr. Thomas G. Roberts
Noonday Asset Management, Ltd., Charlotte, NC
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 2:00 PM-4:00 PM
Folate in Cancer Treatment and Prognosis: A Multi "-Omic" Approach
Cornelia M. Ulrich, Ph.D.
Fred Hutchinson Cancer Research Center, Seattle, WA
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 2:00 PM-4:00 PM
Anti-glycan Autoantibody Signatures of Malignancy Status: Applications of Printed Glycan Array in Cancer Diagnostics and Discovery of Therapeutic Targets
Dr. Margaret E. Huflejt
GlycoMedical Research Institute, La Jolla, CA
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 2:00 PM-4:00 PM
Development and Implementation of Reverse Phase Protein Microarrays for Patient Tailored Therapies
Dr. Emanuel Petricoin
George Mason University
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 2:00 PM-4:00 PM
Innovative Approach to Cancer Biomarker Discovery
Samir M. Hanash, M.D., Ph.D.
Fred Hutchinson Cancer Research Center, Seattle, WA
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 2:00 PM-4:00 PM
Keynote Address: Blueprint of the Breast and Colorectal Cancer Genomes
Dr. Victor E. Velculescu
Johns Hopkins University Oncology Center, Baltimore, MD
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 17, 2007 7:00 PM-8:30 PM
Circulating DNA as a Tumor Biomarker
Dave S. B. Hoon, Ph.D.
John Wayne Cancer Institute, Santa Monica, CA
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 18, 2007 8:00 AM-10:15 AM
Potential of BEAMing Technology to Develop Individualized Cancer Care
Frank Diehl, Ph.D.
Johns Hopkins University, Baltimore, MD
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 18, 2007 8:00 AM-10:15 AM
Detection of Epidermal Growth Factor Receptor Mutations in Serum DNA Using the Scorpion ARMS in Patients with Advanced Non-Small-Cell Lung Cancer
Isamu Okamoto, M.D., Ph.D.
Kinki University School of Medicine, Osaka, Japan
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 18, 2007 8:00 AM-10:15 AM
Detection and Prognostication of Hepatocellular Carcinoma by Quantitative Analysis of Aberrantly Methylated DNA in Serum Using a Non-bisulfite-based Method
K. C. Allen Chan
Chinese University of Hong Kong, Hong Kong, China
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 18, 2007 8:00 AM-10:15 AM
Intrinsic Tumor Capacity Is Within the Genes
Laura J. van't Veer, Ph.D.
The Netherlands Cancer Institute, Amsterdam, The Netherlands
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 18, 2007 10:45 AM-1:00 PM
Expansion of Myeloid Immune Suppressor Cells in Tumor-bearing Host Directly Promotes Tumor Angiogenesis, Tumor Growth, and Metastasis
P. Charles Lin, Ph.D.
Vanderbilt University Medical Center, Nashville, TN
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 18, 2007 10:45 AM-1:00 PM
""Being Prepared:"" Tissue Conditioning in Forming the Pre-Metastatic Niche
Rosandra N. Kaplan, M.D.
Memorial Sloan-Kettering Cancer Center, New York, NY
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 18, 2007 10:45 AM-1:00 PM
Plasma is More Sensitive than Cellular Analysis for Detecting JAK2 Mutations and Determining Zygosity
Dr. Maher X. Albitar
Quest Diagnostics Nichols Institute, San Juan, Capistrano, CA
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 18, 2007 10:45 AM-1:00 PM
Predicting Clinical Activity to Lapatinib: Beyond ErbB2(Her2)
Anne-Marie Martin, Ph.D.
GlaxoSmithKline, Collegeville, PA
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 18, 2007 4:30 PM-6:45 PM
Personalized Therapy Options for Advanced Non-Small Cell Lung Cancer
Roy S. Herbst, M.D., Ph.D.
UT M. D. Anderson Cancer Center, Houston, TX
from 2007 Molecular Diagnostics in Cancer Therapeutic Development conference on September 18, 2007 4:30 PM-6:45 PM
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 25 of 46